KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.96

Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study.

Bei Hu, Patrick M Reagan, Laurie H Sehn, Jeff P Sharman, Mark Hertzberg, Huilai Zhang, Austin Kim, Charles Herbaux, Lysiane Molina, Dai Maruyama, Frank Stenner, Saibah Chohan, Rucha Kothari, Connie Lee Batlevi, Jamie Hirata, Deniz Sahin, Calvin Lee, Matthew Sugidono, Hervé Tilly

Blood Adv 9(10) 2489-2499

PMID40085955
PMCIDPMC12143816
DOI10.1182/bloodadvances.2024014707
发表日期2025-03-14
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

In the phase 3 POLARIX study, Pola-R-CHP (polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone) improved progression-free survival (PFS) vs R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL). This post hoc subgroup analysis of POLARIX evaluated the efficacy and safety of Pola-R-CHP vs R-CHOP in older patients aged ≥60, ≥65, ≥70, and ≥75 years. As of 15 June 2022 (median follow-up, 40 months), 629 patients aged ≥60 years were included (Pola-R-CHP, n = 311; R-CHOP, n = 318). Clinically meaningful improvements in PFS with Pola-R-CHP vs R-CHOP were observed across all age groups, particularly in patients aged ≥70 years whereby the risk of disease progression, relapse, or death was reduced by 37% (unstratified hazard ratio [HR], 0.63; 95% confidence interval [CI], 0.41-0.96). In patients aged ≥60 years, overall survival was similar with Pola-R-CHP vs R-CHOP (unstratified HR, 0. 99; 95% CI, 0.67-1.47). Safety profiles were similar for Pola-R-CHP vs R-CHOP among patients aged ≥60 years, including rates of grade 3 to 4 adverse events (AEs; 62.7% vs 61.5%), grade 3 to 5 infections (15.0% vs 12.9%), and grade 5 AEs (3.6% vs 3.2%); no novel toxicities were reported. Incidence of grade 3 to 4 febrile neutropenia was higher with Pola-R-CHP than R-CHOP (16.3% vs 7.6%), highlighting the importance of granulocyte colony-stimulating factor prophylaxis in older patients receiving Pola-R-CHP. The benefit-risk profile favored Pola-R-CHP vs R-CHOP in older patients with previously untreated DLBCL. This trial was registered at www.ClinicalTrials.gov as #NCT03274492.

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

Figure 1

PFS_for_patients_70_years

PFS

Figure 1 · Panel PFS_for_patients_70_years

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel PFS_for_patients_70_years 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
OS_for_patients_60_years

OS

Figure 1 · Panel OS_for_patients_60_years

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel OS_for_patients_60_years 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.PFS with Pola-R-CHP and R-CHOP in older patients. (A) Aged ≥60 years, (B) ≥65 years, (C) ≥70 years, and (D) ≥75 years from the POLARIX study (efficacy-evaluable population). Unstratified log-rank analysis.
非 KM Figure
Figure 2.OS with Pola-R-CHP and R-CHOP in older patients. (A) Aged ≥60 years, (B) ≥65 years, (C) ≥70 years, and (D) ≥75 years from the POLARIX study (efficacy-evaluable population). Unstratified log-rank analysis.
非 KM Figure